Treatment of osteoporosis with ep2/ep4 receptor selective...

Details Treatment of osteoporosis with ep2/ep4 receptor selective... Treatment of osteoporosis with ep2/ep4 receptor selective...

A - Human Necessities

61

K

A61K 31/216 (2006.01) A61K 31/195 (2006.01) A61K 31/20 (2006.01) A61K 31/381 (2006.01) A61K 31/4015 (2006.01) A61K 31/41 (2006.01) A61K 31/5575 (2006.01) A61K 45/06 (2006.01) A61P 19/08 (2006.01) A61P 19/10 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2334257

This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP2 receptor selective agonists and EP4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP2 receptor and the EP4 receptor.

Affiliated with

Also associated with

Rating

Treatment of osteoporosis with ep2/ep4 receptor selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of osteoporosis with ep2/ep4 receptor selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of osteoporosis with ep2/ep4 receptor selective... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2015445